ImetelChat

“In fact, one of the most comprehensive studies on the matter published just last month in Annals of Hematology by Kuykendall et al. reported a median overall survival in patients that discontinue Incyte's Jakafi of only 13 months. So stating that imetelstat's projected median overall survival of 22 to 24 months is somehow not clinically meaningful in patients headed toward bone marrow failure is completely out of step with the peer-reviewed literature.” Two links below:

First link is the article by George which in my opinion is very good:

https://finance.yahoo.com/news/3-reason ... 00532.html

Second link:

Abstract of article cited by George:

https://link.springer.com/article/10.10 ... 017-3194-4

More and more I feel we will see Imet as first line Tx, as discontinuation rate of Jakafi is pretty high.